Navigation Links
Cepheid Welcomes Executive Vice President of Global Operations
Date:5/7/2013

SUNNYVALE, Calif., May 7, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has appointed Warren C. Kocmond to the position of Executive Vice President, Global Operations, effective May 6, 2013.

Mr. Kocmond joins Cepheid from Lam Research Corporation, where he most recently served as Vice President of Global Operations, responsible for globally dispersed operations including a multi-billion dollar supply chain.  Prior to Lam Research, Mr. Kocmond was Executive Vice President of Global Operations and Quality at Verigy, Ltd., now a wholly owned subsidiary of Advantest Corp.  Mr. Kocmond previously held operations and management positions at Applied Materials and Silicon Graphics, among other companies, and brings well over two decades of relevant experience to Cepheid.

In connection with his employment, the Compensation Committee of Cepheid's Board of Directors has granted Mr. Kocmond an option to purchase 75,000 shares of Cepheid common stock at the closing price of Cepheid common stock on Mr. Kocmond's employment commencement date and restricted stock units in respect of 8,333 shares of Cepheid common stock.  The option will become exercisable by Mr. Kocmond over four years, with 25% vesting on the one-year anniversary of grant and ratably monthly thereafter, so long as Mr. Kocmond continues to be employed or provide services to Cepheid, and will expire after seven years from the grant date.  The restricted stock units will vest over four years, with 25% vesting on the one-year anniversary of the grant and as to an additional 1/16th of the restricted stock units at the end of each three-month period thereafter, so long as Mr. Kocmond continues to be employed or provide services to Cepheid.  The option and restricted stock units were granted as inducement grants pursuant to Section 5635(c)(4) of The NASDAQ Stock Market Rules.

About Cepheid
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400-8377

communications@cepheid.com

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400-8329

investor.relations@cepheid.com
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
8. Cepheid Reports 2012 Second Quarter Results
9. Cepheid Announces Board of Directors Changes
10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
11. Cepheid Reports 2013 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):